The effect of Epizyme Inc.’s tazemetostat in stabilizing disease and its favorable tolerability profile justify accelerated approval for treatment of epithelioid sarcoma despite the limited data available from a single-arm study, a US Food and Drug Administration advisory committee said on 18 December.
The Oncologic Drugs Advisory Committee unanimously endorsed tazemetostat – a first-in-class, oral, EZH2 inhibitor – for treatment of patients with...





